{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:20:26Z","timestamp":1792516826129,"version":"4.5.0"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Vitiligo is a multifactorial reversible skin disorder characterized by distinct white patches that result from melanocyte destruction. Activated CXCR3<jats:sup>+<\/jats:sup> CD8<jats:sup>+<\/jats:sup> T cells promote melanocyte detachment and apoptosis through interferon-gamma (IFN-\u03b3 secretion and chemokines secreted by keratinocytes through the Janus kinase (JAK)\/signal transducer and activator of transcription (STAT)-1 signaling pathway results in further recruitment of CXCR3<jats:sup>+<\/jats:sup> CD8<jats:sup>+<\/jats:sup> T cells and the formation of a positive-feedback loop. JAK inhibitors target the JAK\/STAT pathway and are now approved to treat many immune-related diseases. In the treatment of vitiligo, JAK inhibitors, including ruxolitinib, baricitinib, and tofacitinib, are effective, supporting the implication of the IFN-\u03b3-chemokine signaling axis in the pathogenesis of vitiligo. However, more studies are required to determine the ideal dosage of JAK inhibitors for the treatment of vitiligo, and to identify other inflammatory pathways that may be implicated in the pathogenesis of this condition.<\/jats:p>","DOI":"10.3389\/fimmu.2021.790125","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T06:31:15Z","timestamp":1637217075000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":189,"title":["Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Fei","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000506103","article-title":"Vitiligo: A Review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/JID.2015.398","article-title":"The Vitiligo Impact Patient Scale (VIPs): Development and Validation of a Vitiligo Burden Assessment Tool","volume":"136","author":"Salzes","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0241445","DOI":"10.1371\/journal.pone.0241445","article-title":"Vitiligo and Anxiety: A Systematic Review and Meta-Analysis","volume":"15","author":"Kussainova","year":"2020","journal-title":"PloS One"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15199","article-title":"Vitiligo and Depression: A Systematic Review and Meta-Analysis of Observational Studies","volume":"177","author":"Lai","year":"2017","journal-title":"Br J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3892\/etm.2021.10229","article-title":"Updates and New Medical Treatments for Vitiligo (Review)","volume":"22","author":"Kubelis-Lopez","year":"2021","journal-title":"Exp Ther Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaad.2016.11.010","article-title":"Current and Emerging Treatments for Vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00447-y","article-title":"Vitiligo, From Physiopathology to Emerging Treatments: A Review","volume":"10","author":"Migayron","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/01.lab.0000069521.42488.1b","article-title":"Immunopolarization of CD4+ and CD8+ T Cells to Type-1-Like Is Associated With Melanocyte Loss in Human Vitiligo","volume":"83","author":"Wankowicz-Kalinska","year":"2003","journal-title":"Lab Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells From Vitiligo Patients","volume":"129","author":"van den Boorn","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2016.12.021","article-title":"Suction Blistering the Lesional Skin of Vitiligo Patients Reveals Useful Biomarkers of Disease Activity","volume":"76","author":"Strassner","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2001.01408.x","article-title":"Specific Cytotoxic T Lymphocyte Responses Against Melan-A\/MART1, Tyrosinase and Gp100 in Vitiligo by the Use of Major Histocompatibility Complex\/Peptide Tetramers: The Role of Cellular Immunity in the Etiopathogenesis of Vitiligo","volume":"117","author":"Palermo","year":"2001","journal-title":"J Invest Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: Mechanisms of Pathogenesis and Treatment","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jaad.2003.12.031","article-title":"Topical Tacrolimus Therapy for Vitiligo: Therapeutic Responses and Skin Messenger RNA Expression of Proinflammatory Cytokines","volume":"51","author":"Grimes","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14416","article-title":"Increased Expression of CXCR3 and Its Ligands in Patients With Vitiligo and CXCL10 as a Potential Clinical Marker for Vitiligo","volume":"174","author":"Wang","year":"2016","journal-title":"Br J Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.08.038","article-title":"Vitiligo Skin Is Imprinted With Resident Memory CD8 T Cells Expressing Cxcr3","volume":"138","author":"Boniface","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/pcmr.12219","article-title":"Type I Interferon Signature in the Initiation of the Immune Response in Vitiligo","volume":"27","author":"Bertolotti","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.463","article-title":"A Mouse Model of Vitiligo With Focused Epidermal Depigmentation Requires IFN-Gamma for Autoreactive CD8(+) T-Cell Accumulation in the Skin","volume":"132","author":"Harris","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.09.016","article-title":"Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis During Vitiligo and May Serve as Biomarkers of Disease","volume":"137","author":"Richmond","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.10.048","article-title":"CXCR3 Depleting Antibodies Prevent and Reverse Vitiligo in Mice","volume":"137","author":"Richmond","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00403-017-1792-6","article-title":"Expression of Janus Kinase 1 in Vitiligo & Psoriasis Before and After Narrow Band UVB: A Case-Control Study","volume":"310","author":"Nada","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203925","article-title":"Janus Kinases: Components of Multiple Signaling Pathways","volume":"19","author":"Rane","year":"2000","journal-title":"Oncogene"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01758","article-title":"Interplay Between Janus Kinase\/Signal Transducer and Activator of Transcription Signaling Activated by Type I Interferons and Viral Antagonism","volume":"8","author":"Nan","year":"2017","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nri1604","article-title":"Mechanisms of Type-I- and Type-II-Interferon-Mediated Signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/1203475420972340","article-title":"Cutaneous JAK Expression in Vitiligo","volume":"25","author":"Abdel Motaleb","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e133772","DOI":"10.1172\/jci.insight.133772","article-title":"Type-1 Cytokines Regulate MMP-9 Production and E-Cadherin Disruption to Promote Melanocyte Loss in Vitiligo","volume":"5","author":"Boukhedouni","year":"2020","journal-title":"JCI Insight"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nri3499","article-title":"Metalloproteinases and Their Natural Inhibitors in Inflammation and Immunity","volume":"13","author":"Khokha","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.imlet.2009.09.009","article-title":"Trans-Presentation: A Novel Mechanism Regulating IL-15 Delivery and Responses","volume":"127","author":"Stonier","year":"2010","journal-title":"Immunol Lett"},{"key":"B32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2019.05.011","article-title":"Oxidative Stress-Induced IL-15 Trans-Presentation in Keratinocytes Contributes to CD8(+) T Cells Activation via JAK-STAT Pathway in Vitiligo","volume":"139","author":"Chen","year":"2019","journal-title":"Free Radic Biol Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in Vitiligo Using the Janus Kinase Inhibitor Tofacitinib May Require Concomitant Light Exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.5778","article-title":"Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy","volume":"154","author":"Kim","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18606","article-title":"Open-Label Pilot Study of Tofacitinib 2% for the Treatment of Refractory Vitiligo","volume":"182","author":"Mobasher","year":"2020","journal-title":"Br J Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13348","article-title":"Repigmentation of Vitiligo With Oral Baricitinib","volume":"61","author":"Mumford","year":"2020","journal-title":"Australas J Dermatol"},{"key":"B38","first-page":"394","article-title":"Ruxolitinib, a Selective JAK1 and JAK2 Inhibitor for the Treatment of Myeloproliferative Neoplasms and Psoriasis","volume":"13","author":"Mesa","year":"2010","journal-title":"IDrugs"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1159\/000494613","article-title":"Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study","volume":"235","author":"Almutairi","year":"2019","journal-title":"Dermatology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral Ruxolitinib Induces Hair Regrowth in Patients With Moderate-to-Severe Alopecia Areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119889","article-title":"Plasma Pharmacokinetics and Distribution of Ruxolitinib Into Skin Following Oral and Topical Administration in Minipigs","volume":"590","author":"Persaud","year":"2020","journal-title":"Int J Pharm"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3652","article-title":"Ruxolitinib","volume":"11","author":"Mesa","year":"2012","journal-title":"Nat Rev Drug Discovery"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and Future Status of JAK Inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient With Coexistent Vitiligo and Alopecia Areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645","article-title":"Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-Inhibitor Ruxolitinib Impairs Dendritic Cell Function In Vitro and In Vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"B47","volume-title":"A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)","author":"Incyte","year":"2022"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of Vitiligo With the Topical Janus Kinase Inhibitor Ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.023","article-title":"Treatment of Vitiligo With the Topical Janus Kinase Inhibitor Ruxolitinib: A 32-Week Open-Label Extension Study With Optional Narrow-Band Ultraviolet B","volume":"78","author":"Joshipura","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib Cream for Treatment of Vitiligo: A Randomised, Controlled, Phase 2 Trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(20)32470-3","article-title":"Ruxolitinib Cream for the Treatment of Vitiligo - Authors' Reply","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.11.061","article-title":"Vitiligo: A Comprehensive Overview Part I. Introduction, Epidemiology, Quality of Life, Diagnosis, Differential Diagnosis, Associations, Histopathology, Etiology, and Work-Up","volume":"65","author":"Alikhan","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14055","article-title":"Comorbidities in Vitiligo: Comprehensive Review","volume":"57","author":"Dahir","year":"2018","journal-title":"Int J Dermatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32469-7","article-title":"Ruxolitinib Cream for the Treatment of Vitiligo","volume":"396","author":"Uppal","year":"2020","journal-title":"Lancet"},{"key":"B55","volume-title":"Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)","author":"Incyte","year":"2021"},{"key":"B56","volume-title":"Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)","author":"Incyte","year":"2021"},{"key":"B57","volume-title":"Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo","author":"Incyte","year":"2024"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or Adalimumab Versus Placebo for Psoriatic Arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0001","article-title":"Treatment of Alopecia Areata With Tofacitinib","volume":"153","author":"Ibrahim","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1159\/000514535","article-title":"Biological Therapies for Atopic Dermatitis: A Systematic Review","volume":"237","author":"Zhou","year":"2021","journal-title":"Dermatology"},{"key":"B61","volume-title":"Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo","author":"University Hospital","year":""},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.218164","article-title":"The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer","volume":"351","author":"Coffey","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1047","article-title":"Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients With Relapsed\/Refractory B-Cell Malignancies","volume":"25","author":"Coffey","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B64","volume-title":"Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo","author":"Dermavant Sciences Gmb","year":"2020"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/art.41316","article-title":"Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3\/TEC Inhibitor, in Patients With Moderate-To-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate","volume":"72","author":"Robinson","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 Inhibitor PF-06700841 in Patients With Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"140","author":"Forman","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B67","volume-title":"A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-Segmental Vitiligo Subjects","year":""},{"key":"B68","volume-title":"A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata","year":""},{"key":"B69","volume-title":"A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo","year":""},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15550","article-title":"Heat Shock Protein 70 Potentiates Interferon Alpha Production by Plasmacytoid Dendritic Cells: Relevance for Cutaneous Lupus and Vitiligo Pathogenesis","volume":"177","author":"Jacquemin","year":"2017","journal-title":"Br J Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.790125\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T06:31:26Z","timestamp":1637217086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.790125\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2021.790125"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.790125","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"article-number":"790125"}}